Close Menu

Caprion

The newly launched EndPandemic National Data Consortium brings together seven life sciences and bioinformatics firms in search of treatments and vaccines.

The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.

Caprion said that the acquisition helps it acquire expertise in the analysis of myeloid-derived suppressor cells and expand its geographic coverage.

Roche ran a mock clinical trial in which it used DIA mass spec and targeted proteomics to profile 30 colorectal cancer samples under GCP conditions.

According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.

The company is testing a five-protein panel in longitudinal samples to see if it could help with early detection and prediction of progression in Alzheimer's.

Caprion will use its mass spec platform to measure Alzheimer's-linked proteins in the CSF of more than 200 patients and controls over three or more years.

The company expects its purchase of ImmuneHealth's immune monitoring laboratory will help it win business for clinical work requiring fresh sample analysis.

Caprion said it will use the lab to expand its immune monitoring offering and strengthen its business partnerships and research collaborations in Europe.

Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.

Pages

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.